193 related articles for article (PubMed ID: 20432330)
1. Can we predict which patient will fail drug treatment for overactive bladder? A think tank discussion.
Nitti VW; Kopp Z; Lin AT; Moore KH; Oefelein M; Mills IW
Neurourol Urodyn; 2010 Apr; 29(4):652-7. PubMed ID: 20432330
[TBL] [Abstract][Full Text] [Related]
2. Changing treatments for overactive bladder.
Waine E; Stott M
Nurs Times; 2008 Oct 14-20; 104(41):45-8. PubMed ID: 18979960
[TBL] [Abstract][Full Text] [Related]
3. Overactive bladder symptoms in women: current concepts in patient management.
Easton WA
Can J Urol; 2010 Feb; 17 Suppl 1():12-7. PubMed ID: 20170596
[TBL] [Abstract][Full Text] [Related]
4. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of overactive urinary bladder with imperative urinary incontinence in women].
Neĭmark AI; Riapolova MV; Mel'nik MA
Urologiia; 2010; (2):36-8. PubMed ID: 20967993
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
7. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
8. Redefining response in overactive bladder syndrome.
Payne CK; Kelleher C
BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
[TBL] [Abstract][Full Text] [Related]
9. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
[TBL] [Abstract][Full Text] [Related]
10. [Solifenacin in treatment of the overactive bladder syndrome--diagnosis, clinical management and results].
Slavov Ch; Popov E; Slavov S; Dimitrov R; Doganov N; Chernev T
Akush Ginekol (Sofiia); 2010; 49(3):16-21. PubMed ID: 20734651
[TBL] [Abstract][Full Text] [Related]
11. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
12. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
13. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
15. [Overactive bladder. When it's pressing, immediate help is indicated].
Widhalm S
MMW Fortschr Med; 2008 May; 150(20):44-5. PubMed ID: 18605642
[No Abstract] [Full Text] [Related]
16. The pharmacotherapy of overactive bladder.
Athanasopoulos A
Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
[TBL] [Abstract][Full Text] [Related]
17. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
18. Overactive bladder.
Carr LK
Can J Urol; 2008 Aug; 15 Suppl 1():32-6; discussion 36. PubMed ID: 18700063
[TBL] [Abstract][Full Text] [Related]
19. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.
Brubaker L; Chapple C; Coyne KS; Kopp Z
Urology; 2006 Aug; 68(2 Suppl):3-8. PubMed ID: 16908335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
